Graft vs Host Disease

19 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Immune System Diseases

Treatments and conditions

Graft vs Host Disease
Treatment and conditionWhere it standsTrials
Abatacept for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Alpha-galactosylceramide for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for graft vs host diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Corticosteroids + Ruxolitinib for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Dapagliflozin for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Decidual Stromal Cells for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + FLUDARABINE + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for graft vs host diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose PTCy for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Remestemcel-l for graft vs host diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rovadicitinib for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for graft vs host diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Body Irradiation 12 Gy + Total Body Irradiation 8 Gy for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
αβ T-cells depletion + Cyclophosphamide for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.